{"protocolSection":{"identificationModule":{"nctId":"NCT00539240","orgStudyIdInfo":{"id":"CLIN-022-04F"},"organization":{"fullName":"VA Office of Research and Development","class":"FED"},"briefTitle":"Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI","officialTitle":"Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI"},"statusModule":{"statusVerifiedDate":"2014-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-04"},"primaryCompletionDateStruct":{"date":"2010-04","type":"ACTUAL"},"completionDateStruct":{"date":"2011-11","type":"ACTUAL"},"studyFirstSubmitDate":"2007-10-03","studyFirstSubmitQcDate":"2007-10-03","studyFirstPostDateStruct":{"date":"2007-10-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-02-07","resultsFirstSubmitQcDate":"2014-07-29","resultsFirstPostDateStruct":{"date":"2014-08-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-07-29","lastUpdatePostDateStruct":{"date":"2014-08-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"US Department of Veterans Affairs","class":"FED"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this project is to compare the efficacy (how successful) 1) standard-dose proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely blocks the stomach from producing acid) plus low dose tricyclic antidepressant (nortriptyline 50mg) (TCA); 2) double-dose PPI (rabeprazole 20 mg twice a day); to 3) standard-dose PPI (rabeprazole 20mg once daily) and placebo (an inactive substance, like a sugar pill) to determine the relative symptom resolution and health-related quality of life in gastroesophageal reflux disease (a disease characterized by a burning sensation (heartburn) behind the breast bone caused by a backflow of stomach contents into the esophagus) (GERD) patients who fail standard-dose PPI and you will be randomly assigned (similar to flipping a coin) to one of the three groups.","detailedDescription":"Failure of standard dose PPI to control GERD symptoms has been increasingly encountered in clinical practice (both primary care and sub-specialties) and has become one of the most challenging therapeutic dilemmas in GERD management. It has been estimated that up to 30% of the patients receiving PPI once daily will continue to report typical GERD symptoms \\[1\\]. Presently, increasing the PPI dose has been the standard of care in these patients \\[2\\]. However, success in relieving refractory GERD symptoms with such a therapeutic approach has been extremely limited, resulting in frustration of both the patient as well as the health care provided. Furthermore, patients who fail PPI will continue to seek medical attention and may undergo a variety of invasive or non-invasive tests, and thus consume already limited health care resources. Recent advancement in the understanding of the diverse composition of the different GERD groups as well as symptom generation has led to the recognition of alteration in pain perception as an important contributing factor for PPI failure in some and the presence of non-acid related stimuli in others \\[3\\].\n\nThis study will clarify for the first time the role of pain modulation in patients who failed standard dose of PPI. The clinical experience with doubling the PPI dose, which is the current standard of care, has been very limited and relatively disappointing. Additionally, this study may identify the group of PPI failure patients that may benefit from doubling the dose of PPI and the group that will benefit more from adding a pain modulator. This study is timely, has never been performed and addresses a prevalent emerging clinical dilemma in GI as well as primary care clinics."},"conditionsModule":{"conditions":["Gastroesophageal Reflux Disease"],"keywords":["acid reflux","acid regurgitation","esophagitis","GERD","heartburn","pain","peptic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE"}},"enrollmentInfo":{"count":236,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rabeprazole morning/evening placebo bedtime","type":"PLACEBO_COMPARATOR","description":"AciPhex 20 mg BID and once daily placebo","interventionNames":["Drug: Rabeprazole 20 mg two times, Placebo at bedtime"]},{"label":"Rabeprazole breakfast, placebo dinner and bedtime","type":"PLACEBO_COMPARATOR","description":"AcipHex 20 mg once daily and BID placebo","interventionNames":["Drug: Rabeprazole 20mg, placebo dinner and bedtime"]},{"label":"Rabeprazole breakfast, placebo dinner, nortriptyline bedtime","type":"ACTIVE_COMPARATOR","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily","interventionNames":["Drug: Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant"]}],"interventions":[{"type":"DRUG","name":"Rabeprazole 20mg, placebo dinner and bedtime","description":"Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime","armGroupLabels":["Rabeprazole breakfast, placebo dinner and bedtime"],"otherNames":["AcipHex"]},{"type":"DRUG","name":"Rabeprazole 20 mg two times, Placebo at bedtime","description":"Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime","armGroupLabels":["Rabeprazole morning/evening placebo bedtime"],"otherNames":["Aciphex"]},{"type":"DRUG","name":"Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant","description":"Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime","armGroupLabels":["Rabeprazole breakfast, placebo dinner, nortriptyline bedtime"],"otherNames":["Nortriptyline and Aciphex"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)","description":"the number of days with Symptom Intensity Score \\< 3 (better) for daytime heartburn during week 6 as compared to baseline","timeFrame":"Symptom control after 6 weeks of treatment"},{"measure":"Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline","description":"the number of days with Symptom Intensity Score \\< 3 (better) for nighttime heartburn during week 6 as compared to baseline","timeFrame":"Symptom control after 6 weeks of treatment"},{"measure":"Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)","description":"the number of days with Symptom Intensity Score \\< 3 (better) for acid regurgitation during week 6 as compared to baseline","timeFrame":"Symptom control after 6 weeks of treatment"}],"secondaryOutcomes":[{"measure":"Health Related Quality of Life","description":"SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 - 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean.","timeFrame":"end of study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Currently being treated with a PPI, but continue to experience GERD symptoms (such as heartburn) at least 2 times per week.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to TCA\n* History of serious arrhythmia or use of anti-arrhythmics\n* History of seizures\n* Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital, renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric\n* With evidence or history of drug abuse within the past 6 months\n* Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or adenocarcinoma of the esophagus on endoscopy\n* History of esophagogastric surgery\n* Gastric or duodenal lesions (ulcer, tumor, etc.)\n* Women who are pregnant or of childbearing age who are not on contraception\n* Patients who are unwilling or unable to provide informed consent\n* Insulin dependent diabetes","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Southern Arizona VA Health Care System, Tucson","city":"Tucson","state":"Arizona","zip":"85723","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligibility screening occurred prior to randomization. Of 236 patients enrolled, 68 patients were not randomized due to abnormal endoscopy (14 patients), asymptomatic during run-in period (2 patients), lost to follow-up (11 patients), consent withdrawal, protocol deviation and screen failure (32 patients) and other causes (9 patients).","recruitmentDetails":"Recruitment from GI clinic in VA medical center between 4/19/2006 and 3/31/2010","groups":[{"id":"FG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"FG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"FG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"55"},{"groupId":"FG002","numSubjects":"54"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"48"},{"groupId":"FG002","numSubjects":"39"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"15"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"10"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Number of randomized subjects","groups":[{"id":"BG000","title":"AciPhex 20 mg BID and Once Daily Placebo","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"BG001","title":"AcipHex 20 mg Once Daily and BID Placebo","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"BG002","title":"AcipHex 20 mg Once, Placebo Once, Nortriptyline","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"168"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56","spread":"13.8"},{"groupId":"BG001","value":"54.8","spread":"13.4"},{"groupId":"BG002","value":"56","spread":"11.5"},{"groupId":"BG003","value":"55.6","spread":"13.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"48"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"120"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"168"}]}]}]},{"title":"Body Mass Index","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/meter-squared","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.4","spread":"6.1"},{"groupId":"BG001","value":"29.3","spread":"6.5"},{"groupId":"BG002","value":"29.8","spread":"4.6"},{"groupId":"BG003","value":"29.5","spread":"5.9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)","description":"the number of days with Symptom Intensity Score \\< 3 (better) for daytime heartburn during week 6 as compared to baseline","populationDescription":"intention to treat (ITT)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Symptom control after 6 weeks of treatment","groups":[{"id":"OG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"OG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"OG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.9"},{"groupId":"OG001","value":"5.9","spread":"2.2"},{"groupId":"OG002","value":"6.1","spread":"1.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.04","pValueComment":"P\\<0.05 considered statistically significant. No adjustment for multiple comparisons","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.50","pValueComment":"P\\<0.05 considered statistically significant, No adjustment for multiple comparisons","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity"}]},{"type":"SECONDARY","title":"Health Related Quality of Life","description":"SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 - 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"end of study","groups":[{"id":"OG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"OG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"OG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":"10.3"},{"groupId":"OG001","value":"37.7","spread":"11.0"},{"groupId":"OG002","value":"37.7","spread":"11.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.19","pValueComment":"P\\<0.05 considered statistically significant. No adjustment for multiple comparisons (no post-hoc contrasts performed)","statisticalMethod":"ANCOVA","statisticalComment":"Adjusted for baseline score and personality traits (SCL-90)"}]},{"type":"PRIMARY","title":"Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline","description":"the number of days with Symptom Intensity Score \\< 3 (better) for nighttime heartburn during week 6 as compared to baseline","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Symptom control after 6 weeks of treatment","groups":[{"id":"OG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"OG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"OG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.9"},{"groupId":"OG001","value":"5.8","spread":"2.0"},{"groupId":"OG002","value":"6.0","spread":"1.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.04","pValueComment":"P\\<0.05 considered statistically significant, No adjustment for multiple comparisons","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity."},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.50","pValueComment":"P\\<0.05 considered statistically significant, no adjustment for multiple comparisons","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity"}]},{"type":"PRIMARY","title":"Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)","description":"the number of days with Symptom Intensity Score \\< 3 (better) for acid regurgitation during week 6 as compared to baseline","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Symptom control after 6 weeks of treatment","groups":[{"id":"OG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime"},{"id":"OG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime"},{"id":"OG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.8"},{"groupId":"OG001","value":"5.9","spread":"2.1"},{"groupId":"OG002","value":"6.3","spread":"1.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.04","pValueComment":"P\\<0.05 considered statistically significant. No adjustment for multiple comparisons.","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.20","pValueComment":"P\\<0.05 considered statistically significant. No adjustment for multiple comparisons.","statisticalMethod":"Regression, Linear","statisticalComment":"adjusted for age, sex, BMI and ethnicity."}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"6 weeks","eventGroups":[{"id":"EG000","title":"Arm 1","description":"AciPhex 20 mg BID and once daily placebo\n\nRabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime","seriousNumAffected":0,"seriousNumAtRisk":59,"otherNumAffected":3,"otherNumAtRisk":59},{"id":"EG001","title":"Arm 2","description":"AcipHex 20 mg once daily and BID placebo\n\nRabeprazole 20 mg two times, Placebo at bedtime: Breakfast \\& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime","seriousNumAffected":0,"seriousNumAtRisk":55,"otherNumAffected":1,"otherNumAtRisk":55},{"id":"EG002","title":"Arm 3","description":"AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily\n\nRabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime","seriousNumAffected":0,"seriousNumAtRisk":54,"otherNumAffected":10,"otherNumAtRisk":54}],"otherEvents":[{"term":"Flu like symptoms","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":1,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":54}]},{"term":"skin ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"ulcer on tongue","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":54}]},{"term":"Other, Skin and subcutaneous tissue disorders","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Rash (type unspecified) on face","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":54}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":2,"numAtRisk":54}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":3,"numAtRisk":54}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"\"Stomach cramps\"","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":54}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"\"Drowsiness\"","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":3,"numAtRisk":54}]},{"term":"Other, Renal and urinary disorders","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"\"urinary difficulty\" (type unspecified)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":2,"numAtRisk":54}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":59},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":54}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Recruitment challenges, including difficulty finding patients who \"fail\" PPI but had not already been prescribed doubled dose. Necessitated a no-cost extension to complete recruitment"},"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Christopher Wendel, MS","organization":"Southern Arizona VA Health Care System","email":"christopher.wendel@va.gov","phone":"520 792 1450","phoneExt":"1824"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D005764","term":"Gastroesophageal Reflux"},{"id":"D004941","term":"Esophagitis"},{"id":"D006356","term":"Heartburn"},{"id":"D010146","term":"Pain"}],"ancestors":[{"id":"D015154","term":"Esophageal Motility Disorders"},{"id":"D003680","term":"Deglutition Disorders"},{"id":"D004935","term":"Esophageal Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005759","term":"Gastroenteritis"},{"id":"D012817","term":"Signs and Symptoms, Digestive"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D009461","term":"Neurologic Manifestations"}]},"interventionBrowseModule":{"meshes":[{"id":"D064750","term":"Rabeprazole"},{"id":"D009661","term":"Nortriptyline"}],"ancestors":[{"id":"D053799","term":"2-Pyridinylmethylsulfinylbenzimidazoles"},{"id":"D013454","term":"Sulfoxides"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D011725","term":"Pyridines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001562","term":"Benzimidazoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D003986","term":"Dibenzocycloheptenes"},{"id":"D001567","term":"Benzocycloheptenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"}]}},"hasResults":true}